DUAL WAVELENGTH SPECTROPHOTOMETRIC METHOD FOR SIMULTANEOUS ESTIMATION OF DROTAVERINE HYDROCHLORIDE AND ACECLOFENAC IN THEIR COMBINED TABLET DOSAGE FORM

JYOTESH JAIN*, RIDDHISH PATADIA, DIVYESH VANPARIA, RENU CHAUHAN, SHAILESH SHAH
Department of Quality Assurance, Maliba Pharmacy College, Bardoli-Mahuva Road, Tarsadi, Dist. Surat, 394 350, Gujarat, India
Email: jyoteshjain@yahoo.com

Received: 26 May 2010, Revised and Accepted: 01 July 2010

ABSTRACT
A simple, accurate and precise dual wavelength spectrophotometric method was developed for simultaneous determination of Drotaverine hydrochloride and Aceclofenac in combined pharmaceutical dosage form. The principle for dual wavelength method is “the absorbance difference between two points on the mixture spectra is directly proportional to the concentration of the component of interest”. The wavelengths selected for determination of Drotaverine hydrochloride were 271.5 nm and 280.0 nm, whereas, the wavelengths selected for determination of Aceclofenac were 301.5 nm and 311.0 nm. Methanol was taken as a solvent. Regression analysis of Beer’s plots showed good correlation in concentration range of 8-32 μg/ml for Drotaverine hydrochloride and 10-40 μg/ml for Aceclofenac. Accuracy of method was found between 98.33-101.5%. The precision (intra-day, inter-day and repeatability) of method was found within limits. The proposed method was successfully applied to determination of these drugs in commercial tablets.

Keywords: Aceclofenac, Drotaverine hydrochloride, Dual wavelength method, UV spectrophotometric method.

INTRODUCTION
Chemically, Drotaverine (DV) is (1-{3,4-diehxybeysydine}-6,7-diethoxy-1,2,3,4 tetra hydro isoquinoline) hydrochloride. It is a benzyloquinoline derivative. It is non-anticholinergic, a highly potent spasmylytic agent and has excellent smooth muscle relaxant properties. It causes smooth muscle relaxation by increasing intracellular levels of cyclic adenosine monophosphate (cAMP) secondary to inhibition of phosphodiesterase. Drotaverine has been shown to inhibit platelet aggregation in a dose dependent manner. Aceclofenac (AF) is 2-[(2,6-Dichlorophenyl)amino]benzene acetic acid carboxymethyl ester. It is a non-steroidal anti-inflammatory drug (NSAID) taken to reduce inflammation and as an analgesic reducing pain in conditions such as arthritis or acute injury. Literature survey reveals that AF in bulk and tablet dosage form is official in Indian Pharmacopoeia 2007 and British Pharmacopoeia 2008. Several analytical methods have been reported for estimation of DV which include spectrophotometry5-7, HPLC5, thin layer chromatography9, 10 and voltammetry11. The analytical methods reported for estimation of AF are spectrophotometry12-14, HPLC15-17, LC-MS18 and fluorimetry19. In the present work, a successful attempt has been made to estimate both these drugs simultaneously using dual wavelength UV spectrophotometric method. This study attempts to develop a simple, accurate and precise analytical spectrophotometric method, which can quantify these drugs simultaneously from a combined tablet dosage form. The developed method was validated as per ICH guidelines and found to comply with the acceptance criteria20-21. Structures of both the drugs (DV and AF) are shown in figure 1.

MATERIALS AND METHOD

Apparatus
Instrument used was an UV-Visible double beam spectrophotometer, make: SHIMADZU (model UV-1800) with a pair of 1 cm matched quartz cells. All weighing was done on Shimadzu analytical balance (Model AU-220). Calibrated glasswares were used throughout the work.

Reagents and chemicals
Pure drug samples of DV and AF were obtained as gift samples from Astran Labs, Ahmedabad. Methanol AR was used as solvent.

Marketed formulation
The marketed formulation studied was ESNIL tablet manufactured by Cosmas Pharmaceuticals.

Each tablet contains 100 mg Aceclofenac and 80 mg Drotaverine hydrochloride.

Preparation of standard stock solution
Accurately weighed quantity of DV (80 mg) and AF (100 mg) was transferred to two separate 100 ml volumetric flasks, dissolved in little amount of methanol and diluted to the mark with methanol (stock solutions: 800 μg/ml of DV and 1000 μg/ml of AF).

A simple, accurate and precise dual wavelength spectrophotometric method was developed for simultaneous determination of Drotaverine hydrochloride and Aceclofenac in combined pharmaceutical dosage form. The principle for dual wavelength method is “the absorbance difference between two points on the mixture spectra is directly proportional to the concentration of the component of interest”. The wavelengths selected for determination of Drotaverine hydrochloride were 271.5 nm and 280.0 nm, whereas, the wavelengths selected for determination of Aceclofenac were 301.5 nm and 311.0 nm. Methanol was taken as a solvent. Regression analysis of Beer’s plots showed good correlation in concentration range of 8-32 μg/ml for Drotaverine hydrochloride and 10-40 μg/ml for Aceclofenac. Accuracy of method was found between 98.33-101.5%. The precision (intra-day, inter-day and repeatability) of method was found within limits. The proposed method was successfully applied to determination of these drugs in commercial tablets.

Keywords: Aceclofenac, Drotaverine hydrochloride, Dual wavelength method, UV spectrophotometric method.

INTRODUCTION
Chemically, Drotaverine (DV) is (1-{3,4-diethoxybenzylidene}-6,7-diethoxy-1,2,3,4 tetra hydro isoquinoline) hydrochloride. It is a benzylisoquinoline derivative. It is non-anticholinergic, a highly potent spasmylytic agent and has excellent smooth muscle relaxant properties. It causes smooth muscle relaxation by increasing intracellular levels of cyclic adenosine monophosphate (cAMP) secondary to inhibition of phosphodiesterase. Drotaverine has been shown to inhibit platelet aggregation in a dose dependent manner. Aceclofenac (AF) is 2-[(2,6-Dichlorophenyl)amino]benzene acetic acid carboxymethyl ester. It is a non-steroidal anti-inflammatory drug (NSAID) taken to reduce inflammation and as an analgesic reducing pain in conditions such as arthritis or acute injury. Literature survey reveals that AF in bulk and tablet dosage form is official in Indian Pharmacopoeia 2007 and British Pharmacopoeia 2008. Several analytical methods have been reported for estimation of DV which include spectrophotometry5-7, HPLC5, thin layer chromatography9, 10 and voltammetry11. The analytical methods reported for estimation of AF are spectrophotometry12-14, HPLC15-17, LC-MS18 and fluorimetry19. In the present work, a successful attempt has been made to estimate both these drugs simultaneously using dual wavelength UV spectrophotometric method. This study attempts to develop a simple, accurate and precise analytical spectrophotometric method, which can quantify these drugs simultaneously from a combined tablet dosage form. The developed method was validated as per ICH guidelines and found to comply with the acceptance criteria20-21. Structures of both the drugs (DV and AF) are shown in figure 1.

MATERIALS AND METHOD

Apparatus
Instrument used was an UV-Visible double beam spectrophotometer, make: SHIMADZU (model UV-1800) with a pair of 1 cm matched quartz cells. All weighing was done on Shimadzu analytical balance (Model AU-220). Calibrated glasswares were used throughout the work.

Reagents and chemicals
Pure drug samples of DV and AF were obtained as gift samples from Astran Labs, Ahmedabad. Methanol AR was used as solvent.

Marketed formulation
The marketed formulation studied was ESNIL tablet manufactured by Cosmas Pharmaceuticals.

Each tablet contains 100 mg Aceclofenac and 80 mg Drotaverine hydrochloride.

Preparation of standard stock solution
Accurately weighed quantity of DV (80 mg) and AF (100 mg) was transferred to two separate 100 ml volumetric flasks, dissolved in little amount of methanol and diluted to the mark with methanol (stock solutions: 800 μg/ml of DV and 1000 μg/ml of AF).
Preparation of working standard solution

100 µg/ml of AF solution was prepared by diluting 10 ml of stock solution to 100 ml with methanol. 80 µg/ml of DV solution was prepared by diluting 10 ml of stock solution to 100 ml using methanol.

Dual wavelength method

The utility of dual wavelength data processing program is to calculate the unknown concentration of a component of interest present in a mixture containing both the components of interest and an unwanted interfering component by the mechanism of the absorbance difference between two points on the mixture spectra. This is directly proportional to the concentration of the component of interest, independent of the interfering components. The pre-requisite for dual wavelength method is the selection of two such wavelengths where the interfering component shows same absorbance whereas the component of interest shows significant difference in absorbance with concentration.

Study of overlay spectra and selection of wavelength

By appropriate dilutions from the working standard solutions of 80 µg/ml of DV and 100 µg/ml of AF, the solutions of DV (16 µg/ml) and AF (20 µg/ml) were prepared respectively and scanned over the range of 200-450 nm and the overlay spectra were observed for development of suitable method for analysis. The overlay spectra of DV and AF are shown in figure 2. From the overlay spectra two wavelengths 271.5 nm and 280.0 nm were selected as 1 and 2 for estimation of DV. AF shows the same absorbance at these wavelengths. Similarly, wavelengths 301.5 nm and 311.0 nm were selected as 1 and 2 for estimation of AF. For calibration curve, from the working standard solutions, appropriate dilutions in the range of 8-32 µg/ml and 10-40 µg/ml for DV and AF respectively were prepared and analyzed. Mixed standards were prepared in the ratio of 4:5, as the formulation contains DV and AF 80 mg and 100 mg respectively.

Assay of tablet formulation by dual wavelength spectrophotometry

Ten tablets were weighed and crushed to obtain a fine powder. An accurately weighed tablet powder equivalent to about 80 mg of DV and 100 mg of AF was transferred to 100 ml volumetric flask and dissolved in 50 ml of methanol. The volume was made up to the mark using methanol as solvent. The resulting solution was filtered through Whatman filter paper no.42 and 10 ml of this filtrate was appropriately diluted to get concentration of 80 µg/ml of DV and 100 µg/ml of AF. From the above prepared solution, further dilutions were prepared to get the concentration of DV (16 µg/ml) and AF (20 µg/ml). The absorbance was measured at the selected wavelengths and concentrations were determined. The analysis was done in triplicate.

Method validation

Linearity and range

Aliquots of standard stock solutions of DV and AF were diluted with methanol to get final concentrations in range of 8-32 µg/ml for DV and 10-40 µg/ml for AF. This calibration range was prepared five times and absorbance was measured at respective wavelengths for each drug separately.

Precision

Precision of the methods was determined by performing interday variation, intraday variation and method repeatability studies. In interday variation, the absorbance of standard solutions of DV (8-32 µg/ml) and AF (10-40 µg/ml) were measured on three consecutive days. In intraday variation the absorbances were measured three times in a day. In repeatability study, three concentrations of both the drugs were analysed in triplicate.

Recovery studies

To study the accuracy of the proposed method, recovery studies were carried out by standard addition method at three different levels. Known amount of the two drugs was added to pre-analyzed tablet powder and percentage recoveries were calculated.

Ruggedness

The data for ruggedness were obtained from two different analysts.

RESULTS AND DISCUSSION

Method development and validation

The overlay spectra of the drugs suggested that a dual wavelength spectrophotometric method was a suitable method for simultaneous determination of Drotaverine hydrochloride and Aceclofenac. Methanol was taken as solvent system, as both the drugs were soluble in this solvent. In dual wavelength method, wavelengths 271.5 nm and 280.0 nm were selected for determination of Drotaverine hydrochloride, whereas 301.5 nm and 311.0 nm were selected for determination of Aceclofenac. Optimized method parameters for dual wavelength spectrophotometry are shown in table 1.

<table>
<thead>
<tr>
<th>Table 1: Optimized method parameters for Dual Wavelength spectrophotometry</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Method parameters</strong></td>
</tr>
<tr>
<td>Solvent</td>
</tr>
<tr>
<td>Scanning range</td>
</tr>
<tr>
<td>Scan speed</td>
</tr>
<tr>
<td>Analytical wavelengths for determination of AF</td>
</tr>
<tr>
<td>Analytical wavelengths for determination of DV</td>
</tr>
</tbody>
</table>

Linearity

The calibration curves of Drotaverine hydrochloride and Aceclofenac were linear in the range of 8-32 µg/ml and 10-40 µg/ml respectively. The regression equations of calibration curves were

\[ Y_{DV} = 0.002661X - 0.000214, R^2 = 0.9996 \]  for Drotaverine hydrochloride and

\[ Y_{AF} = 0.007893X + 0.006964, R^2 = 0.9989 \]  for Aceclofenac.

Precision

Relative standard deviations (% R.S.D.) for repeatability were found to be 1.3-2.6% and 1.6-2.7% for Drotaverine
hydrochloride and Aceclofenac, respectively. The intraday precision showed % R.S.D. of 1.79-2.33% for Drotaverine hydrochloride and 1.44-2.12% for Aceclofenac. The interday precision showed % R.S.D. of 2.07-3.67% and 1.59-3.73% for Drotaverine hydrochloride and Aceclofenac, respectively. Results of repeatability, intra day and inter day precision of method is illustrated in table 2.

Accuracy

The percentage recoveries of drugs from marketed formulation were determined by standard addition of pure drugs at three known concentrations and excellent recoveries were obtained at each level. The percent recoveries for Drotaverine hydrochloride and Aceclofenac respectively.

Table 2: Validation parameters for dual wavelength method

<table>
<thead>
<tr>
<th>Parameters</th>
<th>DV (%)</th>
<th>AF (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linearity range</td>
<td>8-32 µg/ml</td>
<td>10-40 µg/ml</td>
</tr>
<tr>
<td>Coefficient</td>
<td>0.9996</td>
<td>0.9989</td>
</tr>
<tr>
<td>Precision</td>
<td>%RSD</td>
<td>%RSD</td>
</tr>
<tr>
<td>Repeatability</td>
<td>1.3-2.6</td>
<td>1.6-2.7</td>
</tr>
<tr>
<td>Intraday</td>
<td>1.79-2.33</td>
<td>1.44-2.12</td>
</tr>
<tr>
<td>Interday</td>
<td>2.07-3.67</td>
<td>1.59-3.73</td>
</tr>
<tr>
<td>%Recovery</td>
<td>98.33-101.5</td>
<td>98.50-100.63</td>
</tr>
<tr>
<td>Ruggedness</td>
<td>1.66-2.81</td>
<td>0.43-2.28</td>
</tr>
</tbody>
</table>

*DV- Drotaverine; AF-Aceclofenac; RSD-Relative Standard Deviation.

Table 3: Recovery studies

<table>
<thead>
<tr>
<th>Name of Drug</th>
<th>Amount of Drug Added (µg/ml)</th>
<th>Dual Wavelength Method</th>
<th>% Recovery*</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>DV</td>
<td>12</td>
<td>101.5</td>
<td>0.0006</td>
<td></td>
</tr>
<tr>
<td>AF</td>
<td></td>
<td>100.63</td>
<td>0.0040</td>
<td></td>
</tr>
<tr>
<td>DV</td>
<td>15</td>
<td>98.91</td>
<td>0.0015</td>
<td></td>
</tr>
<tr>
<td>AF</td>
<td></td>
<td>99.50</td>
<td>0.0015</td>
<td></td>
</tr>
<tr>
<td>DV</td>
<td>20</td>
<td>98.33</td>
<td>0.0010</td>
<td></td>
</tr>
<tr>
<td>AF</td>
<td></td>
<td>99.11</td>
<td>0.0025</td>
<td></td>
</tr>
</tbody>
</table>

*Mean of Three estimations - DV-Drotaverine; AF-Aceclofenac; SD-Standard Deviation.

Application of the method in assay of tablets

The proposed UV method was applied for the determination of Drotaverine hydrochloride and Aceclofenac in their marketed pharmaceutical formulation and the results are shown in table 4. The high percentage recovery (98.33-101.5 %) values confirm the suitability of the proposed method for the routine determination of these components in combined formulation.

<table>
<thead>
<tr>
<th>Method</th>
<th>mg/tablet % of label claim (± S.D.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DV</td>
<td>80 ± 101.5 ± 0.0012</td>
</tr>
<tr>
<td>AF</td>
<td>80 ± 101.7 ± 0.0012</td>
</tr>
</tbody>
</table>

*Average of three determinations;

CONCLUSION

The proposed dual wavelength method gives accurate and precise results for determination of Drotaverine hydrochloride and Aceclofenac in marketed formulation (tablet) without prior separation and is easily applied for routine analysis. The most striking feature of the dual wavelength method is its simplicity and rapidity. Method validation has been demonstrated by variety of tests for linearity, accuracy, precision and ruggedness. The proposed method was successfully applied to determination of these drugs in commercial tablets.

ACKNOWLEDGEMENT

The authors are thankful to Astran Lab, Ahmedabad for providing pure gift samples of Drotaverine hydrochloride and Aceclofenac. The authors are also thankful to the Principal, Maliba Pharmacy College for providing necessary facilities.

REFERENCES

8. Ayad MM, Yousef NF, Abdelatifi HE, Soliman SM. A


